Trials / Withdrawn
WithdrawnNCT04274452
A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP)
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX 113) 10 mg/kg Intravenous in Adult Patients With Primary Immune Thrombocytopenia (ITP)
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- argenx · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind placebo-controlled multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in patients with primary ITP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | efgartigimod | Intravenous infusion of efgartigimod |
| OTHER | Placebo | Intravenous infusion of placebo |
Timeline
- Start date
- 2020-06-29
- Primary completion
- 2021-09-01
- Completion
- 2021-09-01
- First posted
- 2020-02-18
- Last updated
- 2020-09-14
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04274452. Inclusion in this directory is not an endorsement.